# Clinical genome sequencing: three years' experience at a tertiary children's hospital

Runjun D. Kumar<sup>1,3</sup>, Lisa F. Saba<sup>2</sup>, Haley Streff<sup>1,2</sup>, Dolores Lopez-Terrada<sup>2,3,4</sup>, Jennifer Scull<sup>2,3</sup>

<sup>1</sup>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX

<sup>2</sup>Department of Pathology, Texas Children's Hospital, Houston, TX

<sup>3</sup>Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX

<sup>4</sup>Department of Pediatrics, Baylor College of Medicine, Houston, TX

\*Corresponding Author

Jennifer Scull, PhD

One Baylor Plaza, Houston, TX 77030

scull@bcm.edu

## Abstract

**Introduction**: Genome sequencing (GS) may shorten the diagnostic odyssey for patients, but clinical experience with this assay in non-research settings remains limited. Texas Children's Hospital began offering GS as a clinical test to admitted patients in 2020, providing an opportunity to study how GS is utilized, potential for misorders, and outcomes of testing.

**Methods**: We conducted a retrospective review of GS orders for admitted patients for a nearly 3year period from March 2020 through December 2022. We gathered anonymized clinical data from the electronic health record to answer the study questions.

**Results**: The diagnostic yield over 97 admitted patients was 35%. The majority of GS clinical indications were neurologic or metabolic (61%) and most patients were in intensive care (58%). Tests were often characterized as misordered (56%), frequently due to redundancy with prior testing. Patients receiving GS without prior exome sequencing (ES) had higher diagnostic rates (45%) than the cohort as a whole. In two cases, GS revealed a molecular diagnosis that is unlikely to be detected by ES.

**Conclusions**: The performance of GS in clinical settings likely justifies its use as a first-line diagnostic test, but the incremental benefit for patients with prior ES may be limited.

2

## Introduction

Clinical genome sequencing (GS) can identify protein-coding single nucleotide variants, as well as intronic, noncoding, regulatory, copy number variants; and repeat expansions through continuous coverage of the nuclear genome. GS may also analyze the mitochondrial genome. GS can provide results faster than other testing methods, especially sequential testing strategies, and may shorten the diagnostic odyssey.

Despite its benefits, clinical experience with GS is still limited. While it is plausible that GS should serve as a first line test for critically ill neonates<sup>1–5</sup>, more general pediatric populations<sup>6–10</sup>, and some adult populations<sup>11,12</sup>, little research addresses the incremental benefit of GS for patients with prior exome sequencing (ES) or chromosomal microarray (CMA)<sup>13</sup>, and current guidelines do not address combining these testing strategies<sup>14</sup>. The diagnostic yield of GS in unselected patient populations is also underexplored<sup>15</sup>.

In 2020, Texas Children's Hospital (TCH) began offering GS as a clinical test to admitted patients. In 2021 TCH established the Genomic Testing Stewardship Committee (GTSC) to develop evidence-based guidelines for the internal use of GS, ES, CMA, and gene panel testing<sup>16–18</sup>. The GTSC conducted a retrospective review of GS usage at TCH to determine the circumstances in which GS is ordered, the types of misorders that can occur, the diagnostic yield when offered as a clinically reportable test, and how the choice to use GS should be informed by prior testing.

#### **Materials and Methods**

## Sample Identification

We conducted a retrospective review of all genome sequencing (GS) tests performed on patients admitted at TCH from March 2020 through the end of December 2022. Tests were completed on a clinical basis. The review included cancelled tests but excluded tests with pending results. We extracted data from the electronic health record (EHR). The Baylor College of Medicine Institutional Review Board granted a waiver of consent for this study (H-52290).

#### Genome Sequencing

We included multiple types of GS in the review, including proband-only, duo (patient + 1 parent), and trio (patient + 2 parents), with both rapid turn-around (7 days) and standard turn-around times (8-10 weeks). All tests were performed at the same CAP/CLIA certified reference laboratory. Molecular findings, diagnoses, and interpretations were obtained exclusively from the final GS report. Tests performed prior to July 22, 2021 did not include triplet nucleotide repeat analysis or mitochondrial genome sequencing; tests after that date include these analyses.

### Data Collection

The GTSC included two laboratory genetic counselors, one clinical molecular geneticist, and one molecular pathologist. Data was collected from the EHR, including GS reports. Major indications for testing were determined from HPO terms in GS reports. Misorders were identified based on clinic notes. The misorder labels included redundant testing, in which prior testing and clinical workup was sufficiently extensive that the GTSC felt more focused testing would have similar utility to GS; controversial testing, in which there is inadequate evidence supporting the

use of GS for a given indication; and incorrect order or documentation, where the plan for GS was not clinically documented<sup>16</sup>.

#### **Statistics**

R x64 4.0.3 with base package was used for statistical analyses. P-values represent the outcomes of Fisher exact tests, unless otherwise specified.

#### Results

### Circumstances in which GS is ordered

Ninety-seven GS tests for 45 female and 52 male patients were ordered during the study period. The median age was 1.96 years, with a range of 2 days to 25 years old (Figure 1A). Patients were most often on the non-ICU acute care floors (42%), followed by the pediatric ICU (37%), neonatal ICU (12%), and cardiac ICU (8%). The genetics consult service ordered the majority of tests (93%), with neurology being the only other service ordering multiple tests (4%).

The most common major indication was neurologic (52%, Figure 1B). Other common indications included metabolic (9.3%), hematologic/oncologic (8.2%), cardiac (8.2%), and multiple congenital anomalies (8.2%). Seizures were the most common subset of neurologic phenotypes (n=36/50), while developmental delays or regression were most common in the remainder (n=9/14). Patients with neurologic phenotypes had a range of ages (2 days to 25 years, median 2.2 years), and were admitted on all unit types (46% acute care, 40% pediatric ICU, 10% neonatal ICU).

## Test appropriateness

Trio GS was completed in 79 cases (81%). Duo GS was completed in 15 cases (15%), and proband-only GS was completed in three cases (4%). Rapid testing, with a laboratory promoted turn-around-time of seven calendar days, was ordered in 41 cases (42%). There is little guidance on when to order rapid testing, and the use of rapid testing depends on clinical context. However, only 9/41 GS orders from acute care floors were requested as rapid, compared with 32/56 from ICUs (22% versus 57%, odds-ratio 4.66 [95% confidence interval 1.8-13.3], p=0.0008), which is consistent with appropriate use in critically ill patients for whom rapid results may guide clinical management.

The GTSC also identified misorders (Figure 1D). Nearly half of orders were found to be appropriate (n=43/97, 44%). The most common concern was testing redundancy (n=43/97, 44%). For these patients, the most common prior tests were ES (n=30/43), CMA (n=29/43), or both ES and CMA (n=21/43). The GTSC suggested these patients could be tested instead with a combination of ES (or ES reanalysis if applicable), CMA, mitochondrial genome sequencing, and repeat expansion testing, depending on the differential diagnosis and prior testing performed.

#### Outcomes of testing

GS was cancelled in five cases. For cases 68, 77, and 81, trio GS tests were cancelled per reference lab policy for missing parental samples. For cases 71 and 89, the parents requested test cancellation after the family elected transition to palliative care. For the 92 cases with completed testing, turnaround times were within goal timeframes, accounting for delays in sample collection. Turnaround times show a bimodal distribution, reflecting the combination of rapid and standard orders (Figure 1E).

6

A diagnosis was achieved in 34 out of 97 tests (35% diagnostic yield, or 37% of completed tests). Fourteen additional tests were "indeterminate", usually due to a variant of unknown significance (VUS) in a gene linked to the reported phenotype or carrier status in a related gene. As of the time of data collection, no indeterminate cases had been interpreted as diagnostic by the ordering physician. Patients 20, 50, 65, 79, and 93 had prior genetic diagnoses, and GS was ordered to identify potential second diagnoses. GS recapitulated the primary diagnosis in all cases, but only patient 50 received a second diagnosis.

Diagnostic outcome did not vary by unit of admission (p=0.44); the highest diagnostic rate was in the PICU (14/36, 39%), and the lowest in the acute care floors (13/41, 32%). GS had a higher diagnostic rate in patients without prior ES testing compared to those receiving GS after ES (Figure 1F, 29/65 versus 5/32, OR=4.3 [95% CI 1.4-16.1], p=0.006). There was no anti-correlation between GS diagnostic rate and prior CMA, gene panel, mitochondrial genome sequencing, or repeat expansion testing.

### Benefits of genome sequencing over alternative testing

A major goal of the review was to identify scenarios when GS should be recommended after, or instead of, ES. We therefore scrutinized the five patients with positive GS after ES.

For patients 2, 20 and 92, the key molecular finding was previously detected on ES. Patient 2 has *AMMECR1*-associated midface hypoplasia, hearing impairment, elliptocytosis and nephrocalcinosis (MIM# 300990); the P/LP variant was identified on prior ES from 2019 as a VUS. For patient 20, the prior ES actually diagnosed *DIS3L2*-associated Perlman syndrome (MIM# 267000); GS was requested due to suspicion for a second diagnosis. For patient 92, trio GS identified a *de novo* variant in *RYR2* labelled P/LP for *RYR2*-related disease (MIM# 180902).

The variant was identified on prior proband-only ES, but was labeled as a VUS due to unknown inheritance.

Patents 87 and 95 had diagnostic GS and prior ES did not report the key molecular result. Patient 87 was diagnosed with Factor XI deficiency (MIM# 612416) based on a P/LP change, c.166T>C, p.C56R in the *F11* gene. ES was completed less than one year prior, but performed at a different reference laboratory. Patient 95 was diagnosed with *TTN*-related disease (MIM# 188840) based on an inherited P/LP change, c.92883G>A, p.W30961\*. ES was performed in 2015 and reanalyzed in 2019.

We next sought diagnoses not easily detected by ES or CMA, regardless of prior testing. Patient 18 was diagnosed with *MECOM*-related thrombocytopenia (MIM# 616738) due to a 4kb deletion spanning exon 4 of the gene. Patient 58 was diagnosed with *MT-ND6*-associated MELAS (MIM# 516006) due to a c.221C>T, p.A74V change at 39% heteroplasmy. No patients were diagnosed with structural rearrangements or triplet repeat expansions.

# Discussion

In this retrospective review we characterized the performance of GS when widely available for inpatients admitted in a tertiary children's hospital. Specifically, we described the circumstances in which GS was ordered, the appropriateness of GS orders, the diagnostic rates of GS in a pediatric hospitalized population, and the benefits of GS over other testing methods.

Prior studies have supported GS use in ICUs, especially NICUs<sup>3,4</sup>. In contrast, the median age of patients receiving GS in this cohort was 2 years old. Moreover, patients were most frequently on

8

the acute care floors and pediatric ICU. Literature generally supports the use of GS for neurologic phenotypes<sup>13</sup>, and the preponderance of neurologic phenotypes in the dataset was expected. Overall, GS testing was used on older, less critically ill children than expected.

We next assessed the appropriateness of GS in individual cases. We found that rapid testing and trio testing were used as expected. However, over half of orders were characterized as misorders, most often due to redundancy with prior testing, especially ES and CMA. Use of GS for patients with extensive prior testing is warranted if GS offers marked incremental benefits, however our analysis does not demonstrate significant incremental diagnostic yield.

The diagnostic rate for the cohort as a whole was 35% (37% of non-cancelled cases). This aligns with prior literature<sup>14</sup>. Use of GS prior to ES was associated with improved diagnostic yield. Only five patients had positive GS after ES, and in three the prior ES detected the P/LP variant. In the remaining two, the identified P/LP variants were coding variants in well-known disease-causing genes which are detectable by ES in principle.

Only two patients from the cohort had GS molecular diagnoses not detectable by ES. One had a single exon deletion in the gene *MECOM*, and the other had a mitochondrial genome variant. Prior studies have argued that GS will improve diagnostic yields by identifying structural variants that are not detectable by  $ES^{13}$ , but in this cohort no patients fit that description.

Our overall conclusion is that GS has the potential to become a first line genetic test, but its role for patients with extensive prior testing is less clear. Within TCH, the GTSC now recommends that clinicians use GS when three of the following are needed: testing for single gene disorders; testing for copy-number variants; testing for mitochondrial genome disorders; testing for repeat

expansion disorders; rapid results. When prior ES is available, reanalysis of exome data may be used prior to GS<sup>19</sup>.

There are important limitations to this study. Foremost, this data is derived from a single center and may not represent the experiences of other facilities. For example, the use of inpatient GS for chronically ill patients may be due to difficulty receiving GS on an outpatient basis, which may not apply to other facilities. Additionally, the diagnostic yield reported here may be improved through the use of RNA-sequencing or functional studies to characterize VUSs, especially in indeterminate cases, and these techniques may be more accessible in other environments<sup>13,20</sup>

Despite these limitations, this study describes the performance of GS in a real-world setting, with clinicians able to order testing without restrictions. The experience of TCH during its first years offering inpatient GS testing may be instructive to other facilities. Additional ongoing test utilization research is needed regarding the diagnostic utility of GS, especially in the context of existing testing paradigms.

## **Data Availability**

All data described in this study are provided within the article and supplementary materials. Additional de-identified clinical data is available upon request to the corresponding author.

# **Author Contribution**


Conceptualization: R.D.K., J.S.; Data curation: R.D.K., L.F.S., H.S.; Formal analysis: R.D.K.; Writing – original draft: R.D.K.; Writing – review & editing: R.D.K., J.S., D.L.T., H.S., L.F.S.

# **Ethics Declarations**

This study adheres to the principles set out in the Declaration of Helsinki. The study was reviewed by the Baylor College of Medicine Institutional Review Board.

# **Conflicts of Interest**

The authors have no personal conflicts of interest to declare.



**Figure 1.** A) Patient ages, n=97. B) Major indication, based on consensus of the GTSC, n=97. C) Admission unit at time of GS order (Pediatric ICU, Neonatal ICU, Cardiac ICU, or non-ICU floors). Rapid and standard turn-around-time orders are indicated, n=97. D) Types of misorders identified; total > 97 due to cases with multiple errors. E) Turn-around times for assays, from time of order to results reported, n=97. F) Prior testing with exome (ES), chromosomal microarray (CMA), targeted DNA panels (Panel), mitochondrial genome sequencing (Mito), and repeat expansion testing (Repeats) are indicated, as well as row totals. Patients with diagnostic genome sequencing (GS dx) are marked. Columns represent patients, n=97.

Case	Age	Sex	Test	ТАТ	Unit	Major	Prior	High impact molecular finding	GS diagnosis	Misorder
ID	Group		type	(w)		indication			C C C C C C C C C C C C C C C C C C C	code
2	1-5y	Μ	tWGS	15.6	PICU	Endocrine	Y	(LP): AMMECR1 c.887+2T>A; (AOH): Chr12 15.6 Mb	Midface hypoplasia, hearing impairment, elipocytosis, and nephrocalcinosis	Redundant
17	Infant	F	rtWGS	0.9	PICU	Neurology	N	(LP): UGDH c.811+1G>A and (VUS): UGDH c.1051A>G, p.I351V	Developmental and epileptic encephalopathy 84	Redundant
18	Infant	F	rtWGS	5.9	Non-ICU	Heme/Onc	N	(LP): MECOM 4kb exon 4 deletion	Radioulnar synostosis with amegakaryocytic thrombocytopenia 2	Redundant
20	1-5y	Μ	tWGS	10.1	PICU	Anomalies	Y	Homozygous (P): DIS3L2del; (AOH): Chr2 >5Mb	Perlman syndrome	Redundant
26	Neonate	F	rtWGS	1.1	NICU	Metabolic	N	(P): GLDC c.723G>T, p.E575* and (P): GLDC c.2316-1G>A; and secondary finding (P): PMS2 c.825A>G, p.Q275=	Glycine Encephalopathy and Lynch syndrome	NA
28	Neonate	F	rtWGS	2.3	NICU	Anomalies	N	(LP): RAPSN c.133G>A, p.V45M and (LP): RAPSN c.425C>A, p.A142D, (AOH) chrX >5Mb, and secondary finding (P): DSP c.3195C>G, p.Y1065*	Fetal Akinesia deformation sequence 2; Arrythmogenic Right Ventricular Dysplasia 8	NA
30	Neonate	M	rtWGS	2.7	NICU	Anomalies	N	(P): CLPB 880C>T p.Q924* and (LP): CLPB c.455+1G>A	3-methylglutaconic aciduria, type VIIb	Redundant
32	Infant	F	rtWGS	4.4	PICU	Neurology	Ν	(P): POLR3A c.1771-7C>G and (P): POLR3A c.3781G>A, p.E1261K	Wiedermann Rautenstrauch syndrome	Redundant
33	1-5y	Μ	rtWGS	0.7	Non-ICU	Neurology	N	(LP): ARSA c.979+1G>A and (LP): ARSA c.338T>C, p.L113_	Metochromatic Leukodystrophy	NA
34	5-12y	F	tWGS	23.7	Non-ICU	Immunology	Ν	(P): NKFBIA c.95_96delinsTT, p.S32I	Ectodermal dysplasia and immunodeficiency 2	NA
35	Neonate	F	rdWGS	1.1	CICU	Neurology	N	(P): KCNH2 c.991del, p.S331Afs*29	Long QT syndrome 2	NA
36	1-5y	Μ	tWGS	10	Non-ICU	Neurology	Ν	(P): PNPT1 c.1519G>T, p.A507S and (LP): PNPT1 c.1592C>G, p.T531R	Combined oxidative phosphorylation deficiency 13	Redundant
37	5-12y	F	dWGS	12	Non-ICU	Cardiology	N	(P): PKP2 c.1926T>A, p.Y642*	Arrhythmogenic right ventricular dysplasia 9	Controversial
41	Infant	F	rtWGS	1.7	PICU	Heme/Onc	N	(P): RPS26 c.9_12del, p.K4Efs*40	Diamond Blackfan Anemia 10	NA
45	12-18y	F	tWGS	9	Non-ICU	Neurology	N	(P): ATP1A3 c.2305C>T, p.R769C	Dystonia-12	NA
48	Infant	F	rtWGS	0.7	PICU	Immunology	Ν	(P): FLCN c.250-2A>G	Birt-Hogg Dube	Controversial
50	12-18y	F	rdWGS	1.4	PICU	Neurology	N	(P): chr22del and (LP): TYMP c.1040T>C, p.L347P	Phelan McDermid and Mitochondrial DNA Depletion Syndrome 1 (MNGIE)	Redundant
52	Infant	Μ	rtWGS	0.6	PICU	Immunology	Ν	(P): NDUFS7 c.364G>A, p.V122M and (LP): NDUFS7 c.537C>A, p.Y179*	Mitochondrial complex I deficiency, nuclear type 3 (Leigh syndrome)	NA
54	Neonate	M	rdWGS	2.3	NICU	Neurology	N	(P): ARX c.769del, p.R257Afs*68	Proud syndrome	Controversial
56	1-5y	Μ	rtWGS	0.9	PICU	Neurology	N	(LP): OFD1 c.991C>T, p.Q331*	Joubert syndrome, 10	NA
58	12-18y	F	tWGS	10	Non-ICU	Endocrine	N	(P): MT-ND6 c.221C>T, p.A74V (39% heteroplasmy); AOH >5Mb	MT-ND6 related disorders (MELAS)	NA
59	1-5y	F	dWGS	9.9	Non-ICU	Neurology	N	(P): ANKRD11 c.928_934del, p.P310Vfs*56	KBG syndrome	Multiple
65	1-5y	F	tWGS	10	CICU	Cardiology	N	(P): 7q11.23del	Williams syndrome	NA
69	1-5y	Μ	rtWGS	0.6	PICU	Neurology	Ν	(P): RARS2 c.419T>G, p.F140C and (LP): RARS2 c.36+1G>T	Pontocerebellar hypoplasia, RARS2 related	NA
76	Infant	Μ	rtWGS	3.1	PICU	Immunology	N	(P): F8 c.1569 G>T, p.L523=	Hemophilia A	NA
79	12-18y	F	dWGS	9.9	Non-ICU	Anomalies	Ν	(P): OCA2 c.1211C>T, p.T404M and (P): OCA2 c.1327G>A, p.V443I	Oculocutaneous albinism II	NA
83	Infant	Μ	tWGS	10.3	PICU	Endocrine	N	(P): NF1 c.4812C>A, p.Y1604*	Neurofibromatosis type 1	Controversial
84	Infant	F	rtWGS	0.4	PICU	Neurology	N	(P): ATP1A2 c.1022G>A, p.C341Y	ATP1A2-related disorders	NA
87	Infant	Μ	tWGS	10	Non-ICU	Heme/Onc	Y	(LP): F11 c.166T>C, p.C56R	Factor XI deficiency	Redundant
88	12-18y	Μ	pWGS	14.6	CICU	Neurology	N	(P): DMD c.6439-636_7098+908del (exon 45-48 del)	Duchenne/Becker muscular dystrophy	NA
92	12-18y	F	tWGS	10	Non-ICU	Neurology	Y	(LP): RYR2 c.11805G>C, p.L3935F	RYR2-Related disorders	Redundant
93	12-18y	F	tWGS	7.3	Non-ICU	Anomalies	N	(P): dup(21)(p21q22)	Down syndrome	NA
94	5-12y	F	tWGS	10.9	PICU	Neurology	N	(LP): MYBPC3 c.3407_3409del, p.Y1136del	MYBPC3-related disorders	Multiple
95	5-12y	М	tWGS	7	Non-ICU	Metabolic	Y	(LP): TTN c.92883G>A, p.W30961*	TTN-related disorders	Redundant

**Table 1**. The 34 diagnosed patients. Demographic data is shown, as well as high impact molecular findings, including pathogenic (P)

 and likely pathogenic (LP) variants. Corresponding clinical diagnoses are shown as well as misorder codes (see Methods). Patients 20,

 50, 65, 79, and 93 had at least one genetic diagnosis prior to GS.

# References

1. Muriello M. Exome and Whole Genome Sequencing in the Neonatal Intensive Care Unit. *Clin Perinatol.* 2022;49(1):167-179. doi:10.1016/j.clp.2021.11.018

2. French CE, Delon I, Dolling H, et al. Whole genome sequencing reveals that genetic conditions are frequent in intensively ill children. *Intensive Care Med.* 2019;45(5):627-636. doi:10.1007/s00134-019-05552-x

3. Suzuki H, Nozaki M, Yoshihashi H, et al. Genome Analysis in Sick Neonates and Infants: High-yield Phenotypes and Contribution of Small Copy Number Variations. *J Pediatr*. 2022;244:38-48.e1. doi:10.1016/j.jpeds.2022.01.033

4. Bowling KM, Thompson ML, Finnila CR, et al. Genome sequencing as a first-line diagnostic test for hospitalized infants. *Genet Med.* 2022;24(4):851-861. doi:10.1016/j.gim.2021.11.020

5. Kumar RD, Burrage LC, Bartos J, et al. A deep intronic variant is a common cause of OTC deficiency in individuals with previously negative genetic testing. *Mol Genet Metab Rep.* 2021;26:100706. doi:10.1016/j.ymgmr.2020.100706

6. Sun Y, Peng J, Liang D, et al. Genome sequencing demonstrates high diagnostic yield in children with undiagnosed global developmental delay/intellectual disability: A prospective study. *Hum Mutat*. 2022;43(5):568-581. doi:10.1002/humu.24347

7. Sanford EF, Clark MM, Farnaes L, et al. Rapid Whole Genome Sequencing Has Clinical Utility in Children in the PICU. *Pediatr Crit Care Med*. 2019;20(11):1007-1020. doi:10.1097/PCC.00000000002056

8. Lindstrand A, Ek M, Kvarnung M, et al. Genome sequencing is a sensitive first-line test to diagnose individuals with intellectual disability. *Genet Med.* 2022;24(11):2296-2307. doi:10.1016/j.gim.2022.07.022

9. Cao Y, Chau MHK, Zheng Y, et al. Exploring the diagnostic utility of genome sequencing for fetal congenital heart defects. *Prenat Diagn*. 2022;42(7):862-872. doi:10.1002/pd.6151

10. Kumar RD, Meng L, Liu P, et al. Clinical exome sequencing uncovers a high frequency of Mendelian disorders in infants with stroke: A retrospective analysis. *American Journal of Medical Genetics Part A*. n/a(n/a). doi:10.1002/ajmg.a.62967

11. Alkelai A, Greenbaum L, Docherty AR, et al. The benefit of diagnostic whole genome sequencing in schizophrenia and other psychotic disorders. *Mol Psychiatry*. 2022;27(3):1435-1447. doi:10.1038/s41380-021-01383-9

12. Huq AJ, Thompson B, Bennett MF, et al. Clinical impact of whole-genome sequencing in patients with early-onset dementia. *J Neurol Neurosurg Psychiatry*. Published online July 29, 2022:jnnp-2021-328146. doi:10.1136/jnnp-2021-328146

13. Palmer EE, Sachdev R, Macintosh R, et al. Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies. *Neurology*. 2021;96(13):e1770-e1782. doi:10.1212/WNL.000000000011655

14. Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* Published online July 1, 2021. doi:10.1038/s41436-021-01242-6

15. Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and wholegenome sequencing approaches cost-effective? A systematic review of the literature. *Genet Med*. 2018;20(10):1122-1130. doi:10.1038/gim.2017.247

16. Suarez CJ, Yu L, Downs N, Costa HA, Stevenson DA. Promoting appropriate genetic testing: the impact of a combined test review and consultative service. *Genet Med*. 2017;19(9):1049-1054. doi:10.1038/gim.2016.219

17. Riley JD, Procop GW, Kottke-Marchant K, Wyllie R, Lacbawan FL. Improving Molecular Genetic Test Utilization through Order Restriction, Test Review, and Guidance. *J Mol Diagn*. 2015;17(3):225-229. doi:10.1016/j.jmoldx.2015.01.003

18. Kieke MC, Conta JH, Riley JD, Zetzsche LH. The current landscape of genetic test stewardship: A multi-center prospective study. *J Genet Couns*. 2021;30(4):1203-1210. doi:10.1002/jgc4.1403

19. Alfares A, Aloraini T, Subaie LA, et al. Whole-genome sequencing offers additional but limited clinical utility compared with reanalysis of whole-exome sequencing. *Genet Med.* 2018;20(11):1328-1333. doi:10.1038/gim.2018.41

20. Murdock DR, Rosenfeld JA, Lee B. What Has the Undiagnosed Diseases Network Taught Us About the Clinical Applications of Genomic Testing? *Annu Rev Med*. 2022;73:575-585. doi:10.1146/annurev-med-042120-014904